Systematic review:: Helicobacter pylori eradication for the prevention of gastric cancer

被引:83
作者
Fuccio, L. [1 ]
Zagari, R. M. [1 ]
Minardi, M. E. [1 ]
Bazzoli, F. [1 ]
机构
[1] Univ Bologna, Policlin S Orsola, Dipartimento Med Interna & Gastroenterol, I-40138 Bologna, Italy
关键词
D O I
10.1111/j.1365-2036.2006.03183.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Helicobacter pylori is recognized as one of the most significant risk factors for gastric cancer, and H. pylori eradication has been proposed as a possible primary chemo-preventive strategy to reduce gastric cancer incidence. Aim To evaluate the available evidence on the efficacy of H. pylori eradication in the prevention of gastric cancer. Methods Epidemiological, observational and interventional studies, as well as decisional models, were taken into account in this review. Results Large-scale epidemiological studies clearly link H. pylori infection with non-cardia gastric cancer. Current evidence suggests that, in a subpopulation of treated subjects, H. pylori eradication prevents the progression of preneoplastic lesions. Studies that have attempted to evaluate the effect of H. pylori eradication on the incidence of gastric cancer have not provided definitive answers. H. pylori eradication seems to reduce the incidence of gastric cancer in patients without baseline precancerous gastric lesions. Decisional models suggest that H. pylori screening could be cost-effective, but there is not yet sufficient evidence to support the setting up of a general screening programme. Conclusion Helicobacter pylori eradication is a plausible intervention for gastric cancer prevention; however, it seems to be relevant in only a subset of subjects.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 65 条
[11]   Meat intake and risk of stomach and Esophageal adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) [J].
González, CA ;
Jakszyn, P ;
Pera, G ;
Agudo, A ;
Bingham, S ;
Palli, D ;
Ferrari, P ;
Boeing, H ;
del Giudice, G ;
Plebani, M ;
Carneiro, F ;
Nesi, G ;
Berrino, F ;
Sacerdote, C ;
Tumino, R ;
Panico, S ;
Berglund, G ;
Simán, H ;
Nyrén, O ;
Hallmans, G ;
Martinez, C ;
Dorronsoro, M ;
Barricarte, A ;
Navarro, C ;
Quirós, JR ;
Allen, N ;
Key, TJ ;
Day, NE ;
Linseisen, J ;
Nagel, G ;
Bergmann, MM ;
Overvad, K ;
Jensen, MK ;
Tjonneland, A ;
Olsen, A ;
Bueno-De-Mesquita, HB ;
Ocke, M ;
Peeters, PHM ;
Numans, ME ;
Clavel-Chapelon, F ;
Boutron-Ruault, MC ;
Trichopoulou, A ;
Psaltopoulou, T ;
Roukos, D ;
Lund, E ;
Hemon, B ;
Kaaks, R ;
Norat, T ;
Riboli, E .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (05) :345-354
[12]   The time to eradicate gastric cancer is now [J].
Graham, DY ;
Shiotani, A .
GUT, 2005, 54 (06) :735-738
[13]  
Hansen S, 1999, SCAND J GASTROENTERO, V34, P353
[14]  
Honda S, 1998, CANCER RES, V58, P4255
[15]   Meta-analysis of the relationship between cagA seropositivity and gastric cancer [J].
Huang, JQ ;
Zheng, GF ;
Sumanac, K ;
Irvine, EJ ;
Hunt, RH .
GASTROENTEROLOGY, 2003, 125 (06) :1636-1644
[16]  
*IARC, 2004, SCHIST LIV FLUK HEL
[17]   Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia:: a 5-year prospective study of patients with atrophic gastritis [J].
Ito, M ;
Haruma, K ;
Kamada, T ;
Mihara, M ;
Kim, S ;
Kitadai, Y ;
Sumii, M ;
Tanaka, S ;
Yoshihara, M ;
Chayama, K .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (08) :1449-1456
[18]   Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130 [J].
Judd, LM ;
Alderman, BM ;
Howlett, M ;
Shulkes, A ;
Dow, C ;
Moverley, J ;
Grail, D ;
Jenkins, BJ ;
Ernst, M ;
Giraud, AS .
GASTROENTEROLOGY, 2004, 126 (01) :196-207
[19]  
Kang GH, 2001, CANCER RES, V61, P2847
[20]   Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection [J].
Kikuchi, S ;
Kato, M ;
Katsuyama, T ;
Tominaga, S ;
Asaka, M .
HELICOBACTER, 2006, 11 (03) :147-151